The UK Competition Authority accuses a pharmaceutical company to abuse of its dominant position (Concordia)

Drug company accused of abusing its position to overcharge the NHS* The CMA has provisionally found that Concordia abused its dominant position to overcharge the NHS by millions for an essential thyroid drug. The Competition and Markets Authority (CMA) has been investigating how much the pharmaceutical company was charging for liothyronine tablets. It found that last year, the NHS spent

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

UK Competition Authority, The UK Competition Authority accuses a pharmaceutical company to abuse of its dominant position (Concordia), 21 November 2017, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 85545

Visites 258

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues